Sinusitis - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

Sinusitis - Pipeline Review, H2 2016

Sinusitis - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
Sinusitis - Pipeline Review, H2 2016
Published Sep 14, 2016
93 pages — Published Sep 14, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Sinusitis - Pipeline Review, H2 2016, provides an overview of the Sinusitis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Sinusitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Sinusitis and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Sinusitis
- The report reviews pipeline therapeutics for Sinusitis by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Sinusitis therapeutics and enlists all their major and minor projects
- The report assesses Sinusitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Sinusitis


Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Sinusitis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Sinusitis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing stra

  
Source:
Document ID
GMDHC8446IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents24
  List of Tables51
  List of Figures51
Introduction61
  Global Markets Direct Report Coverage61
Sinusitis Overview71
Therapeutics Development81
  Pipeline Products for Sinusitis Overview81
Sinusitis Therapeutics under Development by Companies92
Sinusitis Pipeline Products Glance113
  Late Stage Products111
  Clinical Stage Products121
  Early Stage Products131
Sinusitis Products under Development by Companies141
Sinusitis Companies Involved in Therapeutics Development1512
  AmpliPhi Biosciences Corporation151
  F. Hoffmann-La Roche Ltd.161
  Knopp Biosciences LLC171
  Kyorin Pharmaceutical Co., Ltd.181
  Kyowa Hakko Kirin Co., Ltd.191
  Merck &Co., Inc.201
  Oticpharma Ltd211
  Paratek Pharmaceuticals, Inc.221
  Pfizer Inc.231
  Quorum Innovations LLC241
  Regeneron Pharmaceuticals Inc251
  Therabron Therapeutics, Inc.261
Sinusitis Therapeutics Assessment279
  Assessment by Monotherapy Products271
  Assessment by Target282
  Assessment by Mechanism of Action302
  Assessment by Route of Administration322
  Assessment by Molecule Type342
Drug Profiles3650
  ABSA-01 Drug Profile362
  benralizumab Drug Profile384
  CG-201 Drug Profile421
  dexpramipexole dihydrochloride Drug Profile433
  dupilumab Drug Profile466
  fluticasone propionate Drug Profile522
  KRPAM-1977X Drug Profile542
  omadacycline tosylate Drug Profile566
  omalizumab Drug Profile624
  P-008 Drug Profile661
  PCL-1404 Drug Profile671
  PF-06817024 Drug Profile681
  Qi-117 Drug Profile691
  RG-6149 Drug Profile701
  Small Molecule for Sinusitis Drug Profile711
  Small Molecule to Inhibit Soluble Epoxide Hydrolase for Sinusitis and Allergic Rhinitis Drug Profile721
  Small Molecules for Chronic Rhinosinusitis Drug Profile731
  solithromycin Drug Profile7412
Sinusitis Dormant Projects861
Sinusitis Product Development Milestones875
  Featured News &Press Releases871
    Aug 09, 2016: AmpliPhi Biosciences Confirms Clinical Trial Progress871
    Aug 03, 2016: AmpliPhi Biosciences Completes Enrollment of Its Investigational Phage Therapy Trial Targeting Staphylococcus aureus871
    Apr 20, 2016: AmpliPhi Biosciences Provides Update on Phase I Trial: Phage Therapy Well Tolerated in First Cohort881
    Feb 03, 2016: Nasal polyps can be treated with medicine dupilumab881
    Feb 02, 2016: Sanofi and Regeneron Announce Publication of Positive Phase 2 Dupilumab Data in the Journal of the American Medical Association891
    Jan 20, 2016: AmpliPhi Biosciences Announces Dosing of First Patient in Phase 1 Clinical Trial of AB-SA01891
    Nov 19, 2015: AmpliPhi Signs Clinical Trial Agreement with University of Adelaide to Conduct a Phase I Trial of Bacteriophage Therapy for Treating Staphylococcus aureus Infections901
    Jun 23, 2015: Jubilant Life Sciences receives ANDA approval for Levofloxacin Tablets901
    Sep 30, 2014: Regeneron and Sanofi Announce Positive Phase 2 Top-line Dupilumab Results in Patients with Chronic Sinusitis with Nasal Polyps911
Appendix922
  Methodology921
  Coverage921
  Secondary Research921
  Primary Research921
  Expert Panel Validation921
  Contact Us921
  Disclaimer931

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Sinusitis - Pipeline Review, H2 2016" Sep 14, 2016. Alacra Store. May 11, 2025. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Sinusitis-Pipeline-Review-H2-2016-2088-16531>
  
APA:
Global Markets Direct - Market Research. (2016). Sinusitis - Pipeline Review, H2 2016 Sep 14, 2016. New York, NY: Alacra Store. Retrieved May 11, 2025 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Sinusitis-Pipeline-Review-H2-2016-2088-16531>
  
US$ 2,000.00
$  £  
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.